William Duke

Mr. Duke has more than 20 years of operations, finance and accounting experience with over a decade of that in the life science industry. Mr. Duke joins us from Kaleido Biosciences, Inc., where he served as chief financial offer from November 2019 to April 2022. At Kaleido, he was responsible for all areas of finance and accounting, implemented capital formation strategies to fund operations, and lead the successful completion of financings totaling $115 million. From June 2015 to November 2019, Mr. Duke was chief financial officer of Pulmatrix, Inc., where he oversaw the company’s financial strategy, helped negotiate the company’s first product partnership, and led the successful completion of several public offerings. Prior to that, he was the chief financial officer at Valeritas, Inc. where he was responsible for the strategic planning, development, and leadership of the corporate finance function. Mr. Duke also was senior director of finance at Genzyme Corporation, helping in the sale of the company to Sanofi, and director of finance/accounting at Haemonetics Corporation. Over the course of his career in corporate finance, Mr. Duke has raised more than $260 million in equity and debt financings. He is a certified public accountant and holds a Bachelor of Science degree in Business Administration from Stonehill College and a Master of Business Administration degree from Bentley College.